◎ Sugi Atlas

Atlas / Drug / Dexloxiglumide

Dexloxiglumide

drug
On this page

Also known as CR-2017DexloxiglumidaLoxiglumide (r)-formLoxiglumide, (r)-

Summary

Dexloxiglumide (CHEMBL550781) is a phase-3 clinical-stage small molecule targeting CCKAR; indicated across 2 conditions including irritable bowel syndrome and dyspepsia.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Small molecule
  • Targets: 1 (CCKAR)
  • Indications: 2 conditions
  • Clinical trials: 2
  • Chemistry: 461.4 Da · C21H30Cl2N2O5

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL550781
NameDexloxiglumide
TypeSmall molecule
Max phase3
FDA approvedno
PubChem CID65937
Molecular formulaC21H30Cl2N2O5
Molecular weight461.4
InChIKeyQNQZBKQEIFTHFZ-GOSISDBHSA-N

SMILES: CCCCCN(CCCOC)C(=O)[C@@H](CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl

IUPAC name: (4R)-4-[(3,4-dichlorobenzoyl)amino]-5-[3-methoxypropyl(pentyl)amino]-5-oxopentanoic acid

Also known as: CR-2017, Dexloxiglumida, Dexloxiglumide, Loxiglumide (r)-form, Loxiglumide, (r)-, DEXLOXIGLUMIDE, dexloxiglumide

Patent coverage: 200 distinct patent families (919 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
CCKARCCK1 receptorAntagonist7.50%P32238

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): CCKAR.

Top Reactome pathways

7 total, by targets touching each:

PathwayTargetsGenes
Signal Transduction1CCKAR
Signaling by GPCR1CCKAR
Class A/1 (Rhodopsin-like receptors)1CCKAR
Peptide ligand-binding receptors1CCKAR
GPCR downstream signalling1CCKAR
G alpha (q) signalling events1CCKAR
GPCR ligand binding1CCKAR

Dominant GO biological processes

GO termTargets
neuron migration1
G protein-coupled receptor signaling pathway1
phospholipase C-activating G protein-coupled receptor signaling pathway1
axonogenesis1
forebrain development1
cellular response to hormone stimulus1
cholecystokinin signaling pathway1
regulation of hormone secretion1
signal transduction1

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
irritable bowel syndrome3MONDO:0005052EFO:0000555
dyspepsia2MONDO:0002268EFO:0008533

Clinical trials

Total trials: 2.

Phase distribution

PhaseTrials
PHASE31
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00220090PHASE3COMPLETEDDARWIN Study: A Randomization/Withdrawal Efficacy Study of Dexloxiglumide in Constipation-Predominant Irritable Bowel Syndrome (C-IBS)
NCT00303264PHASE2COMPLETEDThe Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

101 molecules share ≥1 primary target. Top 100 by shared-target count:

MoleculeSourceStatusShared targets
AFATINIBChEMBL + PubChemPhase 4 (approved)CCKAR
ATAZANAVIRChEMBL + PubChemPhase 4 (approved)CCKAR
RIFAMPINChEMBL + PubChemPhase 4 (approved)CCKAR
AMSACRINEChEMBLPhase 4 (approved)CCKAR
BEPRIDILChEMBLPhase 4 (approved)CCKAR
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)CCKAR
CANNABIDIOLChEMBLPhase 4 (approved)CCKAR
CHLORDIAZEPOXIDEChEMBLPhase 4 (approved)CCKAR
CHLORHEXIDINEChEMBLPhase 4 (approved)CCKAR
DASATINIBChEMBLPhase 4 (approved)CCKAR
DAUNORUBICINChEMBLPhase 4 (approved)CCKAR
DESERPIDINEChEMBLPhase 4 (approved)CCKAR
ERLOTINIBChEMBLPhase 4 (approved)CCKAR
FLUVASTATINChEMBLPhase 4 (approved)CCKAR
HYDROXOCOBALAMINChEMBLPhase 4 (approved)CCKAR
INDOCYANINE GREEN ACID FORMChEMBLPhase 4 (approved)CCKAR
LETERMOVIRChEMBLPhase 4 (approved)CCKAR
LURASIDONEChEMBLPhase 4 (approved)CCKAR
NEFAZODONEChEMBLPhase 4 (approved)CCKAR
NIMESULIDEChEMBLPhase 4 (approved)CCKAR
NITAZOXANIDEChEMBLPhase 4 (approved)CCKAR
OSIMERTINIBChEMBLPhase 4 (approved)CCKAR
PACLITAXELChEMBLPhase 4 (approved)CCKAR
PIMOZIDEChEMBLPhase 4 (approved)CCKAR
RAMATROBANChEMBLPhase 4 (approved)CCKAR
RIFAXIMINChEMBLPhase 4 (approved)CCKAR
RIMONABANTChEMBLPhase 4 (approved)CCKAR
RITONAVIRChEMBLPhase 4 (approved)CCKAR
SINCALIDEChEMBLPhase 4 (approved)CCKAR
SUNITINIBChEMBLPhase 4 (approved)CCKAR
TELMISARTANChEMBLPhase 4 (approved)CCKAR
TELOTRISTATChEMBLPhase 4 (approved)CCKAR
TELOTRISTAT ETHYLChEMBLPhase 4 (approved)CCKAR
TIPRANAVIRChEMBLPhase 4 (approved)CCKAR
CE-326597ChEMBLPhase 2CCKAR
DEVAZEPIDEChEMBLPhase 2CCKAR
DIPERODONChEMBLPhase 2CCKAR
LINTITRIPTChEMBLPhase 2CCKAR
LOXIGLUMIDEChEMBLPhase 2CCKAR
NETAZEPIDEChEMBLPhase 2CCKAR
PIRENOXINEChEMBLPhase 2CCKAR
AbirateronePubChemApprovedCCKAR
acetylcysteinePubChemApprovedCCKAR
Aclidinium BromidePubChemApprovedCCKAR
AcyclovirPubChemApprovedCCKAR
AllopurinolPubChemApprovedCCKAR
AlmotriptanPubChemApprovedCCKAR
AlogliptinPubChemApprovedCCKAR
aminolevulinic acidPubChemApprovedCCKAR
AnagrelidePubChemApprovedCCKAR
ApixabanPubChemApprovedCCKAR
ApremilastPubChemApprovedCCKAR
AprepitantPubChemApprovedCCKAR
BinimetinibPubChemApprovedCCKAR
BosentanPubChemApprovedCCKAR
CapsaicinPubChemApprovedCCKAR
chenodiolPubChemApprovedCCKAR
CinacalcetPubChemApprovedCCKAR
ClofarabinePubChemApprovedCCKAR
ClozapinePubChemApprovedCCKAR
CrizotinibPubChemApprovedCCKAR
DacarbazinePubChemApprovedCCKAR
DesloratadinePubChemApprovedCCKAR
Desoxycorticosterone PivalatePubChemApprovedCCKAR
DidanosinePubChemApprovedCCKAR
DihydroergotaminePubChemApprovedCCKAR
DocetaxelPubChemApprovedCCKAR
EnzalutamidePubChemApprovedCCKAR
ErythromycinPubChemApprovedCCKAR
EscitalopramPubChemApprovedCCKAR
EthambutolPubChemApprovedCCKAR
Folic AcidPubChemApprovedCCKAR
FulvestrantPubChemApprovedCCKAR
GanciclovirPubChemApprovedCCKAR
GefitinibPubChemApprovedCCKAR
GlycopyrrolatePubChemApprovedCCKAR
ImipenemPubChemApprovedCCKAR
LeucovorinPubChemApprovedCCKAR
LinagliptinPubChemApprovedCCKAR
MethotrexatePubChemApprovedCCKAR
MoxifloxacinPubChemApprovedCCKAR
NaproxenPubChemApprovedCCKAR
OlanzapinePubChemApprovedCCKAR
Olmesartan MedoxomilPubChemApprovedCCKAR
OlodaterolPubChemApprovedCCKAR
PramipexolePubChemApprovedCCKAR
PropoxyphenePubChemApprovedCCKAR
PyrazinamidePubChemApprovedCCKAR
RufinamidePubChemApprovedCCKAR
saxagliptinPubChemApprovedCCKAR
SildenafilPubChemApprovedCCKAR
SpectinomycinPubChemApprovedCCKAR
SulindacPubChemApprovedCCKAR
TadalafilPubChemApprovedCCKAR
TafamidisPubChemApprovedCCKAR
TamsulosinPubChemApprovedCCKAR
TegaserodPubChemApprovedCCKAR
Tiotropium Bromide MonohydratePubChemApprovedCCKAR
ValacyclovirPubChemApprovedCCKAR
ValganciclovirPubChemApprovedCCKAR

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 29

This page pulls from 29 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot